This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Professor of Medicine, Weill
Cornell Medical College
Attending Physician Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY